SI-BONE, Inc. (SIBN)

Compare

12.32

-0.04

(-0.32%)

At close: 4:00 PM EST

12.32

0.00

(0.00%)

After hours: 4:02 PM EST

SI-BONE, Inc. (NASDAQ:SIBN) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

There's been a major selloff in SI-BONE, Inc. ( NASDAQ:SIBN ) shares in the week since it released its quarterly...

Simply Wall St. 4 days ago

SIBN
-0.32%
SI-BONE Third Quarter 2024 Earnings: EPS Beats Expectations

SI-BONE ( NASDAQ:SIBN ) Third Quarter 2024 Results Key Financial Results Revenue: US$40.3m (up 19% from 3Q 2023). Net...

Simply Wall St. 5 days ago

SIBN
-0.32%
Q3 2024 SI-BONE Inc Earnings Call

Q3 2024 SI-BONE Inc Earnings Call

Thomson Reuters StreetEvents 6 days ago

SIBN
-0.32%
SI-BONE Inc (SIBN) Q3 2024 Earnings Call Highlights: Record Revenue and Path to Profitability

SI-BONE Inc (SIBN) reports a 19% revenue growth and significant strides towards profitability despite challenges from hurricanes and supply issues.

GuruFocus.com 6 days ago

SIBN
-0.32%
Si-Bone (SIBN) Reports Q3 Loss, Lags Revenue Estimates

Si-Bone (SIBN) delivered earnings and revenue surprises of 27.27% and 0.36%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 6 days ago

SIBN
-0.32%
Si-Bone: Q3 Earnings Snapshot

SIBN) on Tuesday reported a loss of $6.6 million in its third quarter. On a per-share basis, the Santa Clara, California-based company said it had a loss of 16 cents. The results topped Wall Street expectations.

Associated Press Finance 7 days ago

SIBN
-0.32%
SI-BONE, Inc. Reports Financial Results for the Third Quarter 2024 and Updates Guidance

Expects to achieve positive Adjusted EBITDA in Fourth Quarter 2024SANTA CLARA, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq:SIBN), a medical device company dedicated to solving sacropelvic disorders, today reported financial results for the quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights (any comparisons are to the prior year period) Worldwide revenue of $40.3 million, representing growth of ~19% U.S. revenue of $38.3 million, representing growth of ~

GlobeNewswire 7 days ago

SIBN
-0.32%
Artivion (AORT) Tops Q3 Earnings and Revenue Estimates

Artivion (AORT) delivered earnings and revenue surprises of 300% and 0.66%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 11 days ago

SIBN
-0.32%
SI-BONE Receives Transitional Pass-Through Payment Status for iFuse Bedrock Granite™

The iFuse Bedrock Granite™ system is a Breakthrough Device Designation technology that provides pelvic fixation and sacroiliac joint fusion, in conjunction with lumbar spinal fusion proceduresSANTA CLARA, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to providing surgical solutions for sacropelvic disorders, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted Transitional Pass-Throu

GlobeNewswire 14 days ago

SIBN
-0.32%
Strength Seen in Si-Bone (SIBN): Can Its 6.9% Jump Turn into More Strength?

Si-Bone (SIBN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks 20 days ago

SIBN
-0.32%
SI-BONE To Report Third Quarter 2024 Financial Results on November 12, 2024

SANTA CLARA, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced it will report financial results for the third quarter of 2024 after market close on Tuesday, November 12, 2024. Management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by registering at this link: https:

GlobeNewswire 28 days ago

SIBN
-0.32%
SIBN Stock Up After First-In-Patient Use of FDA Breakthrough Device

SI-BONE aims to address the unmet clinical needs of complex pelvic fragility fractures by providing a solution that improves both surgical efficiency and patient recovery.

Zacks last month

SIBN
-0.32%
DVA

BAX
$First patients are treated with Si-Bone’s pelvic fracture fixation device$

First patients are treated with Si-Bone’s pelvic fracture fixation device

Si-Bone’s TNT implant system secured 510(k) clearance from the US Food and Drug Administration (FDA) in August 2024.

Medical Device Network last month

SIBN
-0.32%
SI-BONE, Inc. Announces First-In-Patient Procedures with FDA Breakthrough Device for Pelvic Fracture Fixation

SANTA CLARA, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to providing surgical solutions for sacropelvic disorders, today announced first-in-patient procedures with the FDA-designated breakthrough device, iFuse TORQ TNT™ Implant System (TNT). Designed to address the anatomic and biomechanical challenges of pelvic fragility fractures, particularly in patients with poor bone quality, TNT offers a significant advanc

GlobeNewswire last month

SIBN
-0.32%
Wall Street Analysts Think Si-Bone (SIBN) Could Surge 40.3%: Read This Before Placing a Bet

The average of price targets set by Wall Street analysts indicates a potential upside of 40.3% in Si-Bone (SIBN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks 2 months ago

SIBN
-0.32%
SI-BONE (SIBN) Receives FDA Nod for Its TNT Implant System

SI-BONE (SIBN) receives FDA 510(k) clearance for its iFuse TORQ TNT implant system, followed by a Breakthrough Device Designation award by the FDA.

Zacks 2 months ago

SIBN
-0.32%
DGX
SI-BONE To Present at Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024

SANTA CLARA, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference in New York. Management will be hosting a fireside chat on Wednesday, September 4, 2024, at 10:45 a.m. Eastern Time / 7:45 a.m. Pacific Time. Investors interested in listening to the conference call may do so by registe

GlobeNewswire 2 months ago

SIBN
-0.32%
SI-BONE, Inc. Receives 510(k) Clearance and FDA Breakthrough Device Designation for Pelvic Fracture Fixation System

SANTA CLARA, Calif., Aug. 20, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to providing surgical solutions for sacropelvic disorders, announces FDA 510(k) clearance of the iFuse TORQ TNT™ Implant System (TNT). The TNT implant system is designed to meet the specific anatomical and bone mineral density needs of the sacrum and ilium and will serve as the next generation technology for pelvic fragility fracture fixation and sacroilia

GlobeNewswire 2 months ago

SIBN
-0.32%
Wall Street Analysts Believe Si-Bone (SIBN) Could Rally 64.45%: Here's is How to Trade

The consensus price target hints at a 64.5% upside potential for Si-Bone (SIBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks 3 months ago

SIBN
-0.32%
SI-BONE Second Quarter 2024 Earnings: Beats Expectations

SI-BONE ( NASDAQ:SIBN ) Second Quarter 2024 Results Key Financial Results Revenue: US$40.0m (up 20% from 2Q 2023). Net...

Simply Wall St. 3 months ago

SIBN
-0.32%

Performance Overview

Return	SIBN	S&P 500
YTD	-41.31%	+24.05%
1-Year	-29.76%	+31.08%
3-Year	-42.86%	+25.77%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

SI-BONE, Inc. (SIBN)

SI-BONE, Inc. (NASDAQ:SIBN) Just Released Its Third-Quarter Earnings: Here's What Analysts Think

SI-BONE Third Quarter 2024 Earnings: EPS Beats Expectations

Q3 2024 SI-BONE Inc Earnings Call

SI-BONE Inc (SIBN) Q3 2024 Earnings Call Highlights: Record Revenue and Path to Profitability

Si-Bone (SIBN) Reports Q3 Loss, Lags Revenue Estimates

Si-Bone: Q3 Earnings Snapshot

SI-BONE, Inc. Reports Financial Results for the Third Quarter 2024 and Updates Guidance

Artivion (AORT) Tops Q3 Earnings and Revenue Estimates

SI-BONE Receives Transitional Pass-Through Payment Status for iFuse Bedrock Granite™

Strength Seen in Si-Bone (SIBN): Can Its 6.9% Jump Turn into More Strength?

SI-BONE To Report Third Quarter 2024 Financial Results on November 12, 2024

SIBN Stock Up After First-In-Patient Use of FDA Breakthrough Device

First patients are treated with Si-Bone’s pelvic fracture fixation device

SI-BONE, Inc. Announces First-In-Patient Procedures with FDA Breakthrough Device for Pelvic Fracture Fixation

Wall Street Analysts Think Si-Bone (SIBN) Could Surge 40.3%: Read This Before Placing a Bet

SI-BONE (SIBN) Receives FDA Nod for Its TNT Implant System

SI-BONE To Present at Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024

SI-BONE, Inc. Receives 510(k) Clearance and FDA Breakthrough Device Designation for Pelvic Fracture Fixation System

Wall Street Analysts Believe Si-Bone (SIBN) Could Rally 64.45%: Here's is How to Trade

SI-BONE Second Quarter 2024 Earnings: Beats Expectations

Performance Overview